Policy & Regulation
European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis
18 November 2025 - US-based biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) said on Tuesday that the European Commission has approved BRINSUPRI (brensocatib 25mg tablets) for patients wit...
Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer
18 November 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Tuesday that its Phase III lidERA trial of giredestrant met its primary endp...
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
18 November 2025 - Biotheryx Inc, a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, on Monday announced the...
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
18 November 2025 - Clinical-stage biopharmaceutical company Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) on Monday announced results from its joint research with Virginia Commonwealth University (VCU) eva...
Pulmonary Fibrosis Foundation Launches New Five-Year Strategy: The PFF is ME
18 November 2025 - The Pulmonary Fibrosis Foundation (PFF) has introduced a comprehensive five-year strategic plan titled The PFF is ME, developed using the insights and lived experiences of more than...
Privo Technologies reports positive results from non-invasive oral cancer and high-grade dysplasia trial
18 November 2025 - Privo Technologies, a US-based late-stage clinical biopharmaceutical company, on Monday reported results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoenginee...